4D Molecular Therapeutics (FDMT)
(Real Time Quote from BATS)
$5.83 USD
-0.22 (-3.64%)
Updated Aug 6, 2025 12:42 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FDMT 5.83 -0.22(-3.64%)
Will FDMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Other News for FDMT
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | FDMT ...
12 Health Care Stocks Moving In Monday's Intraday Session
FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket